Bioinformatics On the Quest for New Antileishmanial Drugs
A special issue of Tropical Medicine and Infectious Disease (ISSN 2414-6366).
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 5583
Special Issue Editor
Special Issue Information
Dear Colleagues,
Leishmaniasis is caused by parasites of the genus Leishmania (Kinetoplastida, Trypanosomatidae), where roughly 20 parasite species can infect mammals and many of them can lead to human disease. Around 380 million people are at risk for leishmaniasis in 98 countries, and from 1.5 to 2.0 million cases are reported each year, with a significant morbidity and fatality rate. For human use, no vaccine is yet available, and current chemotherapy has several harmful side effects. It is still difficult to transform new research into cost-efficient and accessible biotechnology solutions that attempt to manage and/or enhance the conditions of the disease's therapy. Although new approaches and advancements in antileishmanial drug research are needed for new therapeutic candidates, the biggest obstacles to this goal's success depend on worldwide contributions. Drug discovery and development now heavily rely on bioinformatic methods, which can also lead to quicker, safer, and less expensive drug advancement. Both the pharmaceutical industry and academia rely on in silico drug discovery and development, which has been also focused on new therapeutics against leishmaniasis. While encouraging studies that are followed by in vitro and/or in vivo validation, we invite authors to submit original research articles presenting bioinformatic analysis applied to develop potential novel therapeutics against leishmaniasis.
Potential topics include but are not limited to:
- Nanotechnology-based formulation;
- Molecular docking and molecular dynamics simulations;
- Omics data for new target selection;
- Virtual screening.
Dr. Miguel Angel Chávez-Fumagalli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tropical Medicine and Infectious Disease is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bioinformatics
- drug targets
- drug discovery
- virtual screening
- molecular docking
- pharmacogenomics
- pharmacogenetics
